GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Hologic Inc (NAS:HOLX) » Definitions » Beneish M-Score

Hologic (Hologic) Beneish M-Score : -2.58 (As of Apr. 27, 2024)


View and export this data going back to 1990. Start your Free Trial

What is Hologic Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.58 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Hologic's Beneish M-Score or its related term are showing as below:

HOLX' s Beneish M-Score Range Over the Past 10 Years
Min: -3.4   Med: -2.69   Max: -1.71
Current: -2.58

During the past 13 years, the highest Beneish M-Score of Hologic was -1.71. The lowest was -3.40. And the median was -2.69.


Hologic Beneish M-Score Historical Data

The historical data trend for Hologic's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hologic Beneish M-Score Chart

Hologic Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.67 -2.00 -2.62 -3.28 -2.60

Hologic Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.20 -2.62 -2.59 -2.60 -2.58

Competitive Comparison of Hologic's Beneish M-Score

For the Medical Instruments & Supplies subindustry, Hologic's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hologic's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Hologic's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Hologic's Beneish M-Score falls into.



Hologic Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Hologic for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.1202+0.528 * 1.1562+0.404 * 1.0219+0.892 * 0.8888+0.115 * 1.1834
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0515+4.679 * -0.045741-0.327 * 0.9972
=-2.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $671 Mil.
Revenue was 1013.1 + 945.3 + 984.4 + 1026.5 = $3,969 Mil.
Gross Profit was 567.5 + 500.3 + 367.5 + 585.8 = $2,021 Mil.
Total Current Assets was $3,494 Mil.
Total Assets was $8,470 Mil.
Property, Plant and Equipment(Net PPE) was $527 Mil.
Depreciation, Depletion and Amortization(DDA) was $326 Mil.
Selling, General, & Admin. Expense(SGA) was $976 Mil.
Total Current Liabilities was $899 Mil.
Long-Term Debt & Capital Lease Obligation was $2,537 Mil.
Net Income was 246.5 + 90.6 + -40.5 + 218.5 = $515 Mil.
Non Operating Income was -37.3 + -51 + -40.5 + 13.5 = $-115 Mil.
Cash Flow from Operations was 220 + 258.7 + 332.8 + 206.3 = $1,018 Mil.
Total Receivables was $674 Mil.
Revenue was 1074.2 + 953.2 + 1002.7 + 1435.7 = $4,466 Mil.
Gross Profit was 617.9 + 514.7 + 549.8 + 946.6 = $2,629 Mil.
Total Current Assets was $4,021 Mil.
Total Assets was $9,290 Mil.
Property, Plant and Equipment(Net PPE) was $494 Mil.
Depreciation, Depletion and Amortization(DDA) was $408 Mil.
Selling, General, & Admin. Expense(SGA) was $1,045 Mil.
Total Current Liabilities was $956 Mil.
Long-Term Debt & Capital Lease Obligation was $2,824 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(670.9 / 3969.3) / (673.8 / 4465.8)
=0.169022 / 0.15088
=1.1202

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(2629 / 4465.8) / (2021.1 / 3969.3)
=0.588696 / 0.509183
=1.1562

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (3494.2 + 527) / 8469.5) / (1 - (4021.2 + 494.3) / 9290.3)
=0.525214 / 0.513955
=1.0219

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=3969.3 / 4465.8
=0.8888

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(408 / (408 + 494.3)) / (325.9 / (325.9 + 527))
=0.452178 / 0.382108
=1.1834

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(976.3 / 3969.3) / (1044.6 / 4465.8)
=0.245963 / 0.233911
=1.0515

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((2537.4 + 899) / 8469.5) / ((2823.9 + 956.2) / 9290.3)
=0.405738 / 0.406887
=0.9972

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(515.1 - -115.3 - 1017.8) / 8469.5
=-0.045741

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Hologic has a M-score of -2.58 suggests that the company is unlikely to be a manipulator.


Hologic Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Hologic's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Hologic (Hologic) Business Description

Traded in Other Exchanges
Address
250 Campus Drive, Marlborough, MA, USA, 01752
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (60% of total sales, boosted by pandemic), breast health (14% of sales, suppressed by pandemic), surgical (11%), and skeletal health (1%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
Executives
Charles J Dockendorff director COVIDIEN LTD., 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Scott T Garrett director 35 CROSBY DRIVE, BEDFORD MA 01730
Stephen P Macmillan director, officer: President and CEO 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Essex D Mitchell officer: Div. President, GYN Surgical 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Nanaz Mohtashami director 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Jennifer M Schneiders officer: President, Diag. Solutions 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Benjamin Jordan Cohn officer: Principal Accounting Officer 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Stacey D. Stewart director 5920 WALHONDING ROAD, BETHESDA MD 20816
Elisabeth A Hellmann officer: SVP, Human Resources 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Kevin R Thornal officer: Div. President, Diagnostics 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
John M. Griffin officer: General Counsel 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Karleen Marie Oberton officer: Corp. VP, Finance & Acconting 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Erik S Anderson officer: Div. Pres., Breast & Skeletal 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Jan Verstreken officer: Group President, International 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Allison P Bebo officer: SVP, Human Resources 250 CAMPUS DRIVE, MARLBOROUGH MA 01752

Hologic (Hologic) Headlines